| Autor: |
Cabrera CM; Immunology Section, Department of Hematology, Carlos Haya Regional University Hospital , Málaga , Spain., Sánchez-Godoy L; Clinical Laboratory Service, Carlos Haya Regional University Hospital , Málaga , Spain., Navas-López VM; Pediatric Gastroenterology and Nutrition Unit, Carlos Haya Regional University Hospital , Málaga , Spain. |
| Jazyk: |
angličtina |
| Zdroj: |
Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2019 Aug; Vol. 54 (8), pp. 960-964. Date of Electronic Publication: 2019 Jul 30. |
| DOI: |
10.1080/00365521.2019.1647283 |
| Abstrakt: |
Objectives: Celiac disease (CD) is barely known if the quantitative effect of DQB1*02 (DQ2) double dose in antigen presentation to T-cells has translation into the clinic. For this, we have conducted a case-control study in a cohort of two hundred and nineteen patients with CD. Material and methods: For the control group, individuals were enrolled with single dose of DQ2, carrying DQ2.5 heterodimers in heterozygous state ( n = 109). The cases with CD were diving into three groups: cases with overall DQ2 double dose ( n = 110), DQ2.5 homozygous ( n = 33) and DQ2.5/DQ2.2 heterozygous ( n = 77). Prevalence and associations of demographic, laboratory, histological and clinical characteristics between the control group and cases were studied. Results: No differences were found for the total of 16 variables analyzed between the control group and overall DQ2 double dose as well as DQ2.5 homozygous cases. In contrast to DQ2.5/DQ2.2, heterozygous cases presented a protection factor for developing allergy to airway allergens regarding the control group (OR = 0.210, p = .019). Conclusions: To date, this negative association has not been described. Further studies will be necessary to elucidate the implication of this protection factor in CD. Since, until now the association between CD and allergic diseases has been poorly studied. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
